EGFR and non-small cell lung carcinoma: In NSCLC, the main two driver mutations, with FDA approved targeted therapies, consist of echinoderm microtubule protein like-4/anaplastic lymphoma kinase (EML-4/ALK) translocations and epidermal growth factor receptor (EGFR) mutations.